Latest From Biotech Now

The Case of Misplaced Mountain Magnolias

Magnolia

Amidst the mountains of western North Carolina rests a stand of Sweetbay magnolia trees. This hardly sounds noteworthy, but this story gets interesting. This species of magnolias wouldn’t be easily confused with the much more popular ornamental varieties that are ubiquitous to well manicured southern lawns. Like their popular cousins, these scrawny trees don’t belong in the mountains. They prefer coastal, swampy habitats with wet soils. They are outliers in their present location. So where did Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , ,

If It Happens At BIO International It Gets Attention

Rob Wright

By Rob Wright, Life Science Leader This year’s 2012 BIO International Convention is being held June 18-21 in Boston, and I can’t wait to see the final program. Last year’s event was my first exposure to this conference, and it did not disappoint. Not only was it huge in scale, it was large in scope — having captivating topics littered throughout the program. One that I decided to attend was the Diversity in Biotechnology Summit, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

ticker

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel of experts representing several perspectives on valuation. The session opened with Ben Bonifant, Senior Vice President & Practice Area Leader at Campbell Alliance, presenting results from their Corporate Value Study, which was followed by a discussion examining the key value drivers for emerging companies. Bonifant moderated the panel discussion that featured: Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Picks and Pans – The Buy-Side View for 2012

Survey

What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies? At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , ,